| FGFR2 is a transforming oncogene in human mammary epithelial cells when expressed to levels similar to that found in breast cancer cells with FGFR2 gene amplification. | breast, |
| Despite the low incidence of FGFR2 mutations in ovarian cancer, the two FGFR2 mutations identified in ovarian tumors overlap with the oncogenic mutations previously identified in endometrial tumors. | ovarian,endometrial, |
| FGFR2 has a dual role in the endometrium, by inhibiting cell proliferation in normal endometrium during the menstrual cycle, but acting as an oncogene in endometrial carcinoma. | endometrial, |
| Reprogramming of mesenchymal stem cells by the synovial sarcoma-associated oncogene SYT-SSX2. | sarcoma, |
| HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma. | gastric, |
| FGFR2 and WDR11 are neighboring oncogene and tumor suppressor gene on human chromosome 10q26. | None |
| Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells. | None |
| The role of senescence and prosurvival signaling in controlling the oncogenic activity of FGFR2 mutants associated with cancer and birth defects. | None |
| FGFR2 and FGFR3 gain of function mutants might be facilitators for oncogenic transformation in medulloblastoma. | None |
| The oncogenic nature of mutations observed in FGFR2 and FGFR3. | None |
| FGFR2 signaling underlies p63 oncogenic function in squamous cell carcinoma. | None |
| Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2. | None |
| This study reveals a direct binding event and characterizes the role of TRPA1 ankyrin repeats in regulating FGFR2-driven oncogenic process; a mechanism that is hindered by miRNA-142-3p | None |